Phreesia price target raised to $37 from $36 at Canaccord

Canaccord raised the firm’s price target on Phreesia (PHR) to $37 from $36 and keeps a Buy rating on the shares. The firm views the reaffirming of 2025 revenue guidance and raising of the lower end of adj-EBITDA as favorable, especially considering the mess that the Change Healthcare (UNH) hack has created throughout the healthcare industry.